Earth Science Tech Inc. (OTC: ETST) announced fiscal year 2026 results for the period ended March 31, 2026, reporting growth across key financial metrics as the company continues to execute on its diversified holdings model spanning healthcare, pharmaceuticals, telemedicine, real estate, and consumer businesses. Revenue increased 8% to $35.7 million, gross profit rose 5% to $25.5 million, net income grew 11% to $3.6 million, and total assets increased 27% to $9 million. The results underscore the company's efforts to fully integrate the patient experience from telemedicine consultation to pharmacy dispensing and direct-to-patient fulfillment.
CEO Giorgio R. Saumat attributed the performance to ETST's strategic focus on building a seamless end-to-end platform. "Our goal is to create a frictionless journey for patients, where they can access healthcare providers via telemedicine, have prescriptions filled at our compounding pharmacies, and receive medications directly at home," Saumat said. The diversified holding company operates through several subsidiaries that together form a vertically integrated healthcare ecosystem. The core of the company's value proposition lies in the synergy between its telemedicine platforms, clinical support services, compounding pharmacy operations, and fulfillment capabilities.
The company's healthcare operations are supported by investments in real estate and asset management, as well as a consumer products business. This structure allows ETST to capture value at multiple points along the care delivery chain. The growth in total assets to $9 million reflects ongoing investment in infrastructure to support the integrated model. For more details on the fiscal results, view the full article at https://nnw.fm/u6mhk.
The announcement comes as the healthcare industry increasingly adopts telemedicine and direct-to-patient models, a trend accelerated by the pandemic. ETST's approach of combining virtual care with in-house pharmacy and fulfillment addresses patient demand for convenience and accessibility. By controlling the entire process from consultation to delivery, the company aims to improve patient outcomes and adherence while reducing costs.
ETST's strategy also differentiates it from standalone telemedicine or pharmacy businesses. The integration allows for better data sharing, personalized care, and streamlined operations. The company's consumer products segment adds another revenue stream and brand recognition. Investors can follow the latest news and updates from ETST in the company's newsroom at https://nnw.fm/ETST.
Looking ahead, Earth Science Tech plans to expand its network of telemedicine providers and pharmacy locations, while investing in technology to enhance the patient experience. The company's asset growth provides a foundation for scaling operations. As the healthcare landscape continues to evolve, ETST's integrated model positions it to capture market share in the growing telehealth and specialty pharmacy sectors. The fiscal 2026 results demonstrate early progress, with profitability and revenue growth validating the strategy.
